These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24432894)

  • 1. High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era.
    Blaker YN; Eide MB; Liestøl K; Lauritzsen GF; Kolstad A; Fosså A; Smeland EB; Holte H
    Leuk Lymphoma; 2014 Oct; 55(10):2319-27. PubMed ID: 24432894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era.
    Ban-Hoefen M; Kelly JL; Bernstein SH; Liesveld J; Constine L; Becker M; Milner L; Phillips G; Friedberg JW
    Leuk Lymphoma; 2012 May; 53(5):830-5. PubMed ID: 22023518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation.
    Madsen C; Pedersen MB; Vase MØ; Bendix K; Møller MB; Johansen P; Jensen BA; Jensen P; Munksgaard L; Brown PD; Segel EK; d'Amore FA
    Ann Oncol; 2015 Feb; 26(2):393-9. PubMed ID: 25411416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
    Poiré X; Kline J; Grinblatt D; Zimmerman T; Conner K; Muhs C; Gajewski T; Van Besien K; Smith SM
    Leuk Lymphoma; 2010 Jul; 51(7):1241-50. PubMed ID: 20496994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
    Chen YB; Batchelor T; Li S; Hochberg E; Brezina M; Jones S; Del Rio C; Curtis M; Ballen KK; Barnes J; Chi AS; Dietrich J; Driscoll J; Gertsner ER; Hochberg F; LaCasce AS; McAfee SL; Spitzer TR; Nayak L; Armand P
    Cancer; 2015 Jan; 121(2):226-33. PubMed ID: 25204639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
    Omuro A; Correa DD; DeAngelis LM; Moskowitz CH; Matasar MJ; Kaley TJ; Gavrilovic IT; Nolan C; Pentsova E; Grommes CC; Panageas KS; Baser RE; Faivre G; Abrey LE; Sauter CS
    Blood; 2015 Feb; 125(9):1403-10. PubMed ID: 25568347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
    Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
    Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
    Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
    Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
    Kruger PC; Cooney JP; Turner JH
    Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation.
    Villa D; Crump M; Keating A; Panzarella T; Feng B; Kuruvilla J
    Ann Oncol; 2013 Jun; 24(6):1603-9. PubMed ID: 23425946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
    Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
    Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.
    Mei M; Wondergem MJ; Palmer JM; Shimoni A; Hasenkamp J; Tsai NC; Simpson J; Nademanee A; Raubitschek A; Forman SJ; Krishnan AY
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):2072-5. PubMed ID: 25079874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of autologous stem cell transplantation for patients with aggressive non-Hodgkin lymphoma who had bone marrow involvement at initial diagnosis in the pre-rituximab era.
    Yano S; Asai O; Dobashi N; Osawa H; Takei Y; Takahara S; Otsubo H; Ogasawara Y; Yamaguchi Y; Saito T; Minami J; Hoshi Y; Usui N
    Clin Lymphoma Myeloma; 2007 Mar; 7(5):361-3. PubMed ID: 17562246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
    Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
    Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO).
    García-Noblejas A; Cannata-Ortiz J; Conde E; González Barca E; Gutiérrez N; Rojas R; Vidal MJ; Ramírez MJ; Jiménez-Ubieto A; García-Ruiz JC; Sancho JM; López A; Ríos Rull P; Novelli S; Albo C; Debén G; López-Guillermo A; Nicolás C; González de Villambrosia S; Mercadal S; Martín García-Sancho A; Arranz R
    Ann Hematol; 2017 Aug; 96(8):1323-1330. PubMed ID: 28536895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dose-intensive immunochemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of 29 newly diagnosed young patients with medium/high risk diffuse large B-cell lymphoma].
    Yi S; Liu W; Lyu R; Li Z; Xu Y; Sui W; Huang W; Wang T; Deng S; Liu H; Fu M; Zou D; Qiu L
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):546-50. PubMed ID: 24985182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
    Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
    Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.